Goldman Sachs Lifts Tgt on Human Genome Sciences (HGSI) to $30, Sees As Acquisition Candidate

Goldman Sachs lifted their price target on Human Genome Sciences, Inc. (Nasdaq: HGSI) from $24 to $30, reiterating their Buy rating, citing an optimistic view of Benlysta approval for lupus.  The firm suggests the drug has a $4.3 billion blockbuster potential.

The firm said because Benlysta is a scarce asset it makes Human Genome Sciences an "attractive acquisition candidate." The firm set a new implied acquisition value of $34.

Real-Time Market Moving News Two-Weeks FREE http://www.streetinsider.com/premium_content.php

You May Also Be Interested In

• Barclays Comments on Wesco Aircraft Holdings (WAIR) Acquisition of Interfast; Deal Accretive to 2013
• Barclays Reiterates an 'Equalweight' on Lexington Realty Trust (LXP); Growing Pipeline, But Waiting on Cash in 2013
• Barclays on U.S. Specialty Pharmaceuticals: Model Updates on FRX, MRX, WCRX & PCRX

Create E-mail Alert Related Categories

Analyst Comments, Rumors

Related Entities

Citi

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?

Follow StreetInsider.com On Twitter